# Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

> **NCT03653052** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Simon C Pacey, MD** · enrollment: 18 (actual)

## Conditions studied

- Oesophageal Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03653052
- **Lead sponsor:** Simon C Pacey, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-30
- **Primary completion:** 2021-11-11
- **Final completion:** 2026-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03653052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03653052, "Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03653052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*